You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for MNI 137
MNI 137 is a selective negative allosteric modulator of group II mGlu receptors (IC50 values are 8.3 and 12.6 nM for human and rat mGlu2 inhibition of glutamate-induced calcium mobilization). Displays no activity at mGlu1, mGlu4, mGlu5 or mGlu8 receptors in a calcium mobilization assay.
Compound Libraries for MNI 137
Technical Data for MNI 137
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for MNI 137
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for MNI 137
The following data is based on the product molecular weight 341.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.86 mL||29.31 mL||58.62 mL|
|2.5 mM||1.17 mL||5.86 mL||11.72 mL|
|5 mM||0.59 mL||2.93 mL||5.86 mL|
|25 mM||0.12 mL||0.59 mL||1.17 mL|
References for MNI 137
References are publications that support the biological activity of the product.
Hemstapat et al (2007) A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J.Pharmacol.Exp.Ther. 322 254 PMID: 17416742
If you know of a relevant reference for MNI 137, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: MNI 137, MNI 137 supplier, MNI137, glutamate, mGluRs, receptors, group, II, negative, allosteric, modulators, NAMs, selective, Glutamate, (Metabotropic), Group, Receptors, 4388, Tocris Bioscience
Citations for MNI 137
Citations are publications that use Tocris products.
Currently there are no citations for MNI 137. Do you know of a great paper that uses MNI 137 from Tocris? Please let us know.
Reviews for MNI 137
There are currently no reviews for this product. Be the first to review MNI 137 and earn rewards!
Have you used MNI 137?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.